

Resource Summary Report

Generated by SPARC SAWG on Aug 11, 2026

BV421 Mouse Anti-Human CD34 Antibody

RRID:AB_2687922

Type: Antibody

Proper Citation

BD Biosciences Cat# 562577, RRID:AB_2687922

Antibody Information

URL: http://antibodyregistry.org/AB_2687922

Proper Citation: BD Biosciences Cat# 562577, RRID:AB_2687922

Target Antigen: CD34

Host Organism: mouse

Clonality: monoclonal

Comments: Flow cytometry

Antibody Name: BV421 Mouse Anti-Human CD34 Antibody

Description: This monoclonal targets CD34

Target Organism: human

Clone ID: 581

Antibody ID: AB_2687922

Vendor: BD Biosciences

Catalog Number: 562577

Record Creation Time: 20250819T231955+0000

Record Last Update: 20250820T050050+0000

Ratings and Alerts

No rating or validation information has been found for BV421 Mouse Anti-Human CD34 Antibody.

No alerts have been found for BV421 Mouse Anti-Human CD34 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Pham J, et al. (2025) Nanobioreactor detection of space-associated hematopoietic stem and progenitor cell aging. *Cell stem cell*, 32(9), 1403.

Shang K, et al. (2025) CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models. *Cell reports. Medicine*, 6(6), 102148.

Mayerhofer C, et al. (2025) OGFOD1 enables AML chemo- and nutrient stress resistance by regulating protein synthesis. *Cell metabolism*.

Montalban-Bravo G, et al. (2024) Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia. *Cell reports. Medicine*, 5(6), 101585.

Kawakami E, et al. (2023) Complement factor D targeting protects endotheliopathy in organoid and monkey models of COVID-19. *Cell stem cell*, 30(10), 1315.

Pei S, et al. (2023) A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy. *Cancer discovery*, 13(9), 2032.

Zhao J, et al. (2023) Human hematopoietic stem cell vulnerability to ferroptosis. *Cell*, 186(4), 732.

van der Werf I, et al. (2023) Detection and targeting of splicing deregulation in pediatric acute myeloid leukemia stem cells. *Cell reports. Medicine*, 4(3), 100962.

van Gils N, et al. (2022) Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persists. *iScience*, 25(9), 105013.

Jayavelu AK, et al. (2022) The proteogenomic subtypes of acute myeloid leukemia. *Cancer cell*, 40(3), 301.

Ganan-Gomez I, et al. (2022) Isolation, culture, and immunophenotypic analysis of bone marrow HSPCs from patients with myelodysplastic syndromes. *STAR protocols*, 3(4), 101764.

Chagraoui J, et al. (2021) UM171 Preserves Epigenetic Marks that Are Reduced in Ex Vivo Culture of Human HSCs via Potentiation of the CLR3-KBTBD4 Complex. *Cell stem cell*, 28(1), 48.

Mondala PK, et al. (2021) Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. *Cell stem cell*, 28(4), 623.

Stengel KR, et al. (2021) Definition of a small core transcriptional circuit regulated by AML1-ETO. *Molecular cell*, 81(3), 530.

Kim SP, et al. (2021) Mutant U2AF1-induced alternative splicing of H2afy (macroH2A1) regulates B-lymphopoiesis in mice. *Cell reports*, 36(9), 109626.

Jiang Q, et al. (2021) Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution. *Cell reports*, 34(4), 108670.

Cardoso A, et al. (2021) Interleukin-10 induces interferon- γ -dependent emergency myelopoiesis. *Cell reports*, 37(4), 109887.

Jonsson A, et al. (2020) Transcriptional profiles of human islet and exocrine endothelial cells in subjects with or without impaired glucose metabolism. *Scientific reports*, 10(1), 22315.

Grootens J, et al. (2019) Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis. *EBioMedicine*, 43, 150.

Tomellini E, et al. (2019) Integrin- $\alpha 3$ Is a Functional Marker of Ex Vivo Expanded Human Long-Term Hematopoietic Stem Cells. *Cell reports*, 28(4), 1063.